Monograph Details
|
|
Pain & Pyrexia
> Narcotic analgesics
|
|
BUPRENEX |
| Manufacturer |
|
Reckitt Benckiser Pharmaceuticals, Inc. |
| Legal Classification |
|
CV |
| Pharmacological Class |
|
Opioid (agonist-antagonist). |
| Generic Name |
|
Buprenorphine (as HCl) 0.3mg/mL; inj. |
| Indications |
|
Moderate to severe pain. |
| Children |
|
Under 2 yrs: not recommended. 2–12 yrs: 2–6micrograms/kg every 4–8 hrs, depending on clinical response. |
| Adults |
|
0.3mg by deep IM or slow IV at up to 6 hr intervals as needed. May repeat once, 30–60 minutes after initial dose. |
| Precautions |
|
Impaired respiratory, renal, hepatic, thyroid, adrenocortical or biliary tract function. Head injury. Increased intracranial pressure. CNS depression or coma. Toxic psychoses. Urethral stricture. Acute alcoholism. Delirium tremens. Kyphoscoliosis. Potentially hazardous activity. Drug abusers. Children. Elderly. Debilitated. Labor and delivery. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Potentiation with alcohol, other CNS depressants, general anesthetics, phenothiazines, MAOIs. Respiratory, cardiac collapse possible with diazepam. May precipitate withdrawal in opioid-dependent persons. |
| Adverse Reactions |
|
Sedation, vertigo, nausea, vomiting, hypotension, miosis, headache, diaphoresis, hypoventilation, respiratory or CNS depression. |
| How Supplied |
|
Amps (1mL)—10 |
|
|
|
|
